nach oben

Pediatric Drugs

Erschienen in:

01.04.2013 | Systematic Review

Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis

verfasst von: Noor B. Almandil, Ying Liu, Macey L. Murray, Frank M. C. Besag, Katherine J. Aitchison, Ian C. K. Wong

Erschienen in: Pediatric Drugs | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aims of this study were to provide a systematic review and meta-analysis of the effects of atypical antipsychotics in children and adolescents on weight gain (primary objective) and other metabolic parameters (secondary objective).

Methods

A systematic literature review and meta-analysis of double-blind, randomized, controlled trials were conducted. The data sources used were as follows: EMBASE, PubMed, BIOSIS, International Pharmaceutical Abstracts, The Cochrane database (Clinical Trials), Clinical Trials Government Registry, The metaRegister of Controlled Trials, WHO (World Health Organization) Clinical Trials Registry Platform, and PsycINFO^®. Hand searching was also carried out by examining the reference lists of identified studies. Double-blind, randomized, controlled trials investigating the metabolic adverse effects (weight gain, lipid, glucose, and prolactin level abnormalities) associated with atypical antipsychotic use in children and adolescents aged ≤18 years were included, irrespective of whether the investigation of adverse effects was a primary or secondary endpoint.

Results

We identified 21 studies of drug versus placebo that met the inclusion criteria, with a total of 2,455 patients, 14 studies for risperidone (1,331 patients), three for olanzapine (276 patients), and four for aripiprazole (848 patients). Compared with placebo, the mean weight increases for each drug were olanzapine 3.45 kg (95 % CI 2.93–3.98), risperidone 1.77 kg (95 % CI 1.35–2.20), and aripiprazole 0.94 kg (95 % CI 0.65–1.24). Regarding other metabolic abnormalities, eight studies reported statistically significant increases in prolactin with risperidone; two reported a statistically significant increase in glucose, total cholesterol, and prolactin with olanzapine; and three studies reported a statistically significant decrease in prolactin with aripiprazole. Data on lipid, glucose, and prolactin level changes were too limited to allow us to perform a meta-analysis.

Conclusions

Olanzapine, risperidone, and aripiprazole were all associated with statistically significant weight gain. Olanzapine was associated with the most weight gain and aripiprazole the least. For the secondary outcome, although a number of active comparator trials were identified, data were not available for meta-analysis and were too limited to allow firm conclusions to be drawn.

Jones P, Barnes TR, Davies L, et al. Randomised controlled trial of the effect of quality of life of second vs. first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry. 2006;63:1079–87.PubMedCrossRef

Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in treatment of children and adolescents. Psychiatr Serv. 1999;50:171–4.PubMed

Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behaviour disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243–54.PubMedCrossRef

Glick I, Murray S, Hu R, et al. Treatment with atypical antipsychotics: new indications and new population. J Psychiatr Res. 2001;35:187–91.PubMedCrossRef

Nasrallah N. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28:83–96.PubMedCrossRef

Findling RL, Robb A, Nyilas M, et al. A multiple-centre, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432–41.PubMedCrossRef

Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder. Am J Psychiatry. 2008;165:1420–31.PubMedCrossRef

Chang KD. The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry. 2008;69(suppl.4):4–8.PubMed

Kryzhanovskaya LA, Plouch CK, Xu W, et al. The safety of olanzapine in adolescents with schizophrenia or bipolar disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70:247–58.PubMedCrossRef

10.

Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systemic review and pooled analysis of short term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687–700.PubMedCrossRef

11.

Wong ICK, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89:1131–2.PubMedCrossRef

12.

Rani F, Byrne PJ, Murray ML, Wong ICK, et al. Epidemiological features of antipsychotics prescribing to children and adolescents in primary care in United Kingdom. Pediatrics. 2008;121:1002–9.PubMedCrossRef

13.

Martin A, Leslie D. Trends in psychotropic medications costs for children and adolescents, 1997–2000. Arch Pediatr Adolesc Med. 2003;157:997–1004.PubMedCrossRef

14.

Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol. 2001;39:1–14.CrossRef

15.

Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480–91.PubMed

16.

Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60–71.PubMedCrossRef

17.

Fleischhaker C, Heister P, Hennighausen K, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol. 2006;16:308–16.PubMedCrossRef

18.

Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public health crisis common sense cure. Lancet. 2002;360:473–82.PubMedCrossRef

19.

Lissau I, Sorensen TI. Parental neglect during childhood and increased risk of obesity in young adulthood. Lancet. 1994;343:324–7.PubMedCrossRef

20.

Srinivasan SR, Myers L, Berenson G. Predictability of childhood adiposity and insulin for developing Insulin resistance syndrome in young adulthood. The Bogalusa Heart Study. Diabetes. 2002;51:204–9.PubMedCrossRef

21.

Johonson JG, Cohen P, Kasen S, et al. Childhood adversities associated with the risk for eating disorder or weight problems during adolescents or early adulthood. Am J Psychiatry. 2002;159:394–400.CrossRef

22.

Correll C, Carlson H. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771–91.PubMedCrossRef

23.

Almandil NB, Wong ICK. Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed. 2011;96:192–6.PubMedCrossRef

24.

Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.PubMedCrossRef

25.

Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;159:1686–96.

26.

Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–63.PubMedCrossRef

27.

Pringsheim T, Lam D, Ching H, Pattens S. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomised controlled trials. Drug Saf. 2011;34(8):651–68.PubMedCrossRef

28.

De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26:144–58.PubMedCrossRef

29.

Egger M, Smith GB, Altman D. Systemic review in health care: meta-analysis in context. London: BMJ Publishing Group; 2001. p. 23–66.CrossRef

30.

Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–900.PubMedCrossRef

31.

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomised clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRef

32.

Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.

33.

Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18:140–56.PubMedCrossRef

34.

Scahill L, Leckman JF, Schultz RT, et al. A placebo controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130–5.PubMedCrossRef

35.

Spettigue W, Buchholz A, Henderson K, et al. Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial. BMC Pediatr. 2008;8:4.PubMedCrossRef

36.

Delbello MP, Schwiers ML, Rosenberg HL, et al. A double blind randomised placebo controlled study of quetiapine as adjunctive treatment of adolescent mania. Psychiatry. 2002;41:1216–23.

37.

Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509–16.PubMedCrossRef

38.

Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239–48.PubMedCrossRef

39.

Van Bellinghen M, De Troch C. Risperidone in the treatment of disturbances in children and adolescents with borderline intellectual functioning: a double-blind placebo controlled trial. J Child Adolesc Psychopharmacol. 2001;11:5–13.PubMedCrossRef

40.

Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026–36.PubMedCrossRef

41.

Aman MG, DeSmedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337–46.PubMedCrossRef

42.

McCracken JT, McGough J, Shah B, etal.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–21.

43.

Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634–41.PubMedCrossRef

44.

Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163:402–10.PubMedCrossRef

45.

Nagaraj R, Shinghi P, Malhi P. Risperidone in children with autism: randomised, placebo-controlled, double blind study. J Child Neurol. 2006;21(6):450–5.PubMed

46.

Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46:558–65.PubMedCrossRef

47.

Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545–50.PubMedCrossRef

48.

Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16:575–87.PubMedCrossRef

49.

Haas M, Unis AS, Armenteros J, et al. A 6 week randomized double blind placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611–21.PubMedCrossRef

50.

Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized double blind placebo controlled study. Bipolar Disord. 2009;11(11):687–700.PubMedCrossRef

51.

Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16:541–8.PubMedCrossRef

52.

Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547–56.PubMedCrossRef

53.

Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: A 6 week randomised double blind placebo controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60–70.PubMedCrossRef

54.

Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder co-morbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70:756–64.PubMedCrossRef

55.

Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–40.PubMedCrossRef

56.

Marcus RN, Owen R, Kamen L, et al. A placebo controlled fixed does study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9.PubMedCrossRef

57.

Barzman DH, Delbello MP, Adler CM, et al. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsive and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16:665–70.PubMedCrossRef

58.

Keefe R, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;166:985–95.CrossRef

59.

Buchsbaum MS, Haznedar MM, Aronowitz J, et al. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr Res. 2007;94:293–305.PubMedCrossRef

60.

Emsley RA, Risperidone working group. Risperidone in the treatment of first episode psychotic patients: a double blind multicentre study. Schizophr Bull. 1999;25:721–9.PubMedCrossRef

61.

Emsley R, Rabinowitz J, Medori R, et al. Remission in early psychosis: rates, predictors and clinical and functional outcome correlates. Schizophr Res. 2007;89:129–39.PubMedCrossRef

62.

Facorro BC, Iglesias RP, Bonilla MR, et al. A practical clinical trial comparing haloperidol, risperidone and olanzapine for acute treatment of first episode nonaffective psychosis. J Clin Psychiatry. 2006;67:1511–21.CrossRef

63.

Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008;18:307–16.PubMedCrossRef

64.

Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64:1362–9.PubMedCrossRef

65.

Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):26–36.PubMed

66.

Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Inter Clin Psychopharmacol. 2001;16:197–203.CrossRef

67.

Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–9.PubMedCrossRef

68.

Beasley CM, Sutton VK, Hamilton SH, et al. A double blind randomized placebo controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 2003;23:582–94.PubMedCrossRef

69.

Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337–43.PubMedCrossRef

70.

Ross RG, Novins D, Farley GK, et al. A 1-year open label trial of olanzapine in school age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003;13:301–9.PubMedCrossRef

71.

Haapasalo-Pesu KM, Saarijärvi S. Olanzapine induces remarkable weight gain in adolescent patients. Eur Child Adolesc Psychiatry. 2001;10:205–8.PubMedCrossRef

72.

National Institute for Health and Clinical Excellence (NICE). Mental health and behavioural disorders. London: NICE; 2006.

73.

Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4): CD006569.

74.

Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction on aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244–53.PubMedCrossRef

75.

Aitchison KJ, Mir A, Shivakumar K, et al. Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. J Psychopharmacol. 2011;25(5):675–84. doi:10.1177/0269881109358198.PubMedCrossRef

Titel: Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis
verfasst von: Noor B. Almandil
Ying Liu
Macey L. Murray
Frank M. C. Besag
Katherine J. Aitchison
Ian C. K. Wong
Publikationsdatum: 01.04.2013
Verlag: Springer International Publishing AG
Erschienen in: Pediatric Drugs / Ausgabe 2/2013
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-013-0016-6

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis